These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11427349)

  • 1. The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans.
    McCargar L; Crail D; Dansereau R; Myers W; Lane M
    Int J Pharm; 2001 Jul; 222(2):191-7. PubMed ID: 11427349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water.
    Perkins AC; Wilson CG; Frier M; Blackshaw PE; Dansereau RJ; Vincent RM; Wenderoth D; Hathaway S; Li Z; Spiller RC
    Int J Pharm; 2001 Jul; 222(2):295-303. PubMed ID: 11427359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations.
    Perkins AC; Wilson CG; Frier M; Vincent RM; Blackshaw PE; Dansereau RJ; Juhlin KD; Bekker PJ; Spiller RC
    Int J Pharm; 1999 Sep; 186(2):169-75. PubMed ID: 10486435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
    Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
    Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis.
    Perkins AC; Frier M; Blackshaw PE; Spiller RC; Fairbairn KJ; Dansereau RJ; Kinghorn T; San P; Hosking D
    Int J Pharm; 2006 Mar; 311(1-2):20-5. PubMed ID: 16431045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.
    Perkins AC; Wilson CG; Frier M; Blackshaw PE; Juan D; Dansereau RJ; Hathaway S; Li Z; Long P; Spiller RC
    Aliment Pharmacol Ther; 2001 Jan; 15(1):115-21. PubMed ID: 11136284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
    Walker AD; Adachi JD
    Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers.
    Simanjuntak R; Setiawati E; Yunaidi DA; Handayani LR; Setiawati A; Utami BS; Rosa TA; Sholeh AB
    Drug Res (Stuttg); 2014 Mar; 64(3):136-40. PubMed ID: 24002927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophageal irritation due to alendronate sodium tablets: possible mechanisms.
    Peter CP; Handt LK; Smith SM
    Dig Dis Sci; 1998 Sep; 43(9):1998-2002. PubMed ID: 9753265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compatibility of risedronate sodium tablets with food thickeners.
    Dansereau RJ; Crail DJ
    Am J Health Syst Pharm; 2008 Nov; 65(22):2133-6. PubMed ID: 18997142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
    Dansereau RJ; Crail DJ; Perkins AC
    Curr Med Res Opin; 2008 Apr; 24(4):1137-45. PubMed ID: 18334082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dosage form and formulation factors on the adherence of drugs to the esophagus.
    Marvola M; Rajaniemi M; Marttila E; Vahervuo K; Sothmann A
    J Pharm Sci; 1983 Sep; 72(9):1034-6. PubMed ID: 6631689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
    Lanza FL; Hunt RH; Thomson AB; Provenza JM; Blank MA
    Gastroenterology; 2000 Sep; 119(3):631-8. PubMed ID: 10982755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of pH-responsive alginate raft formulation of risedronate for reduced esophageal irritation.
    Jang SW; Lee JW; Ryu DS; Son M; Kang MJ
    Int J Biol Macromol; 2014 Sep; 70():174-8. PubMed ID: 24995633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence.
    Ringe JD; van der Geest SA; Möller G
    Drugs Aging; 2006; 23(7):569-78. PubMed ID: 16930085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal transit of model mini-tablet controlled release oral dosage forms in fasted human volunteers.
    Podczeck F; Course N; Newton JM; Short MB
    J Pharm Pharmacol; 2007 Jul; 59(7):941-5. PubMed ID: 17637188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
    Zegels B; Eastell R; Russell RG; Ethgen D; Roumagnac I; Collette J; Reginster JY
    Bone; 2001 Jan; 28(1):108-12. PubMed ID: 11165950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of size and shape of tablets on their esophageal transit.
    Channer KS; Virjee JP
    J Clin Pharmacol; 1986 Feb; 26(2):141-6. PubMed ID: 3950057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Episcleritis secondary to risedronate].
    Viñas G; Olivé A; Holgado S; Costa J
    Med Clin (Barc); 2002 Apr; 118(15):598-9. PubMed ID: 12015954
    [No Abstract]   [Full Text] [Related]  

  • 20. Extemporaneous procedures for dissolving risedronate tablets for oral administration and for feeding tubes.
    Dansereau RJ; Crail DJ
    Ann Pharmacother; 2005 Jan; 39(1):63-7. PubMed ID: 15590875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.